NEW YORK ( TheStreet) -- Shares of GSI Group (Nasdaq: GSIG) were gapping down Monday morning with an open price 78.4% lower than Friday's closing price. The stock closed at $11.55 Friday and opened today's trading at $2.50. The average volume for GSI Group has been 116,200 shares per day over the past 30 days. GSI Group has a market cap of $383.7 million and is part of the technology sector and electronics industry. Shares are up 12.9% year to date as of the close of trading on Friday. GSI Group Inc. designs, develops, manufactures, and sells precision motion control devices and associated precision technologies, photonics-based solutions, and semiconductor systems. Its Precision Technology segment provides lasers, optics, air bearing spindles, encoders, and thermal printers. The company has a P/E ratio of 17.2, below the average electronics industry P/E ratio of 17.4 and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates GSI Group as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. You can view the full GSI Group Ratings Report. Get more investment ideas from our investment research center. Interested in other stocks that are gapping down? Get free SMS text alerts sent to you when the action happens by texting DOWN to 95370 or select from multiple alert options.
HOST // Robert Powell
Retirement Planning Event
More from Markets
Dow Advances as Investors Keep an Eye on the Federal Reserve
Stocks rise Tuesday as investors turn their attention to the beginning of the two-day Federal Reserve meeting.
Jim Cramer on What Could Happen to Elon Musk's Twitter
Jim Cramer wrote about the three different scenarios that could happen to Elon Musk as Judge Nathan considers her decision.
Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer
Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.